Catalio Capital Management — 2025 Investments
4 investments dated 2025 · listed companies and verified rows first · show all
Cartography develops antibody-based cancer therapies using single-cell sequencing and computational biology to identify precise cellular targets.
AI & Machine LearningBiotechDeep TechMedical DevicesSouth San Francisco, US
Max Mumbach(Founding Scientist, Target Discovery)Jeffrey Verboon(Founding Scientist, Computational Biology)Ansu Satpathy(Founder)Kevin Parker(Chief Executive Officer)Kevin Parker, PhD(Chief Executive Officer, Board Director; co-founder)Ansuman Satpathy, MD, PhD(Co-founder; Board Director)
Co-investors8VCAndreessen HorowitzArtis VenturesGlobal BioAccess FundHAWKTAILPfizer Venture Investments+6 more
Character Bio is a precision medicine company that integrates genomics, longitudinal clinical data, imaging, and AI-based biomarker analysis to identify genetic drivers of progressive polygenic eye diseases such as age-related macular degeneration and glaucoma.
AI & Machine LearningBiotechDigital HealthJersey City, US
Cheng Zhang(Executive Officer, Director)
BoardVivek Garipalli(Director)Nick Olsen(Director)Peter DiLaura(Director)
Co-investorsaMoonCantos VenturesCatalio Capital Management, LPDuke Capital PartnersLifeforce CapitalSanofi Ventures+3 more
Imbria Pharmaceuticals develops novel cardiovascular disease treatments that target cardiac energy metabolism, with a lead drug candidate, ninerafaxstat, in clinical trials for non-obstructive hypertrophic cardiomyopathy.
BiotechDigital Health
Alvin Shih(CEO)Albert M. Kim(Chief Medical Officer)
Co-investorsAN Venture PartnersRA CapitalSanofi VenturesSV Health Investors
Star Therapeutics develops treatments aimed at addressing real-world patient needs.
BiotechSouth San Francisco, US
Adam Rosenthal(Founder & CEO)Jason Hafler(Director)Nancy Stagliano(Director)Michelle Carpenter(Executive Officer)Carl Gordon(Director)Matthew Fust(Director)
Co-investorsFrazier Life SciencesOrbiMedRA CapitalSanofi VenturesSofinnova VenturesAgent Capital+8 more
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.